Get the Stockscreener App
43.43
2.43%
0.88
Guardant Health Inc stock is traded at $43.43, with a volume of 737.38K.
It is up +2.43% in the last 24 hours and down -8.38% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$42.55
Open:
$42.71
24h Volume:
737.38K
Relative Volume:
0.36
Market Cap:
$5.24B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-10.24
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
+2.70%
1M Performance:
-8.38%
6M Performance:
+77.39%
1Y Performance:
+129.75%
1-Day Range:
$42.12
$43.88
1-Week Range:
$40.28
$44.01
52-Week Range:
$15.81
$50.89
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
43.45 | 5.24B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
525.61 | 198.19B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
207.50 | 148.92B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
127.98 | 36.52B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
440.50 | 35.63B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
188.02 | 33.12B | 15.41B | 1.37B | 2.11B | 7.50 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts - MarketBeat
ARK Investment Management LLC Has $43.99 Million Stock Position in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health (NASDAQ:GH) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
(GH) Technical Data - Stock Traders Daily
New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change - Yahoo Finance
Guardant Health (NASDAQ:GH) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
Scotiabank Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock - MarketBeat
Guardant Health (GH): Among the Best Performing Mid Cap Stocks to Buy According to Analysts - Insider Monkey
Guardant Health Stock Surges Amid Analyst Optimism - TipRanks
Liquid Biopsy Market Worth US$11.3 billion at a robust CAGR of 11.9% | MarketsandMarkets™. - GlobeNewswire Inc.
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year? - MSN
Guardant Health (NASDAQ:GH) Stock Price Down 6.9% Following Weak Earnings - MarketBeat
Guardant Health (NASDAQ:GH) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Guardant accuses Natera of poaching employees, stealing trade secrets - MedTech Dive
Canaccord raises Guardant Health stock target to $60, maintains buy - Investing.com India
Biopsy Devices Market Is Booming Worldwide 2025-2032 | Guardant - openPR
Guardant Health Tops Q4 Revenue Forecast - MSN
Guardant Health price target raised to $56 from $42 at TD Cowen - Yahoo Finance
Guardant Health Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Guardant Health director Tariq Musa sells $5,606 in stock By Investing.com - Investing.com Australia
Guardant Health sues rival Natera over cancer-testing trade secrets - Reuters.com
Guardant Health director Tariq Musa sells $5,606 in stock - Investing.com India
Guardant Health stock falls after Natera lawsuit (GH:NASDAQ) - Seeking Alpha
Natera Stole Guardant Cancer Test Trade Secrets, Suit Says - Bloomberg Law
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday? - Benzinga
UBS Adjusts Guardant Health Price Target to $65 From $40, Maintains Buy Rating -February 21, 2025 at 10:34 am EST - Marketscreener.com
Guardant Health Earnings: Results and Guidance in Line With Expectations; Shares Fairly Valued - Morningstar
Guardant Health Leads the Way in Blood-Based Single Cancer Screening - Morningstar
Guardant Health, Inc. (NASDAQ:GH) Q4 2024 Earnings Call Transcript - Insider Monkey
Guardant Health announces debt exchange transactions - MSN
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates - MSN
Guardant Health Inc (GH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook - BioSpace
Baillie Gifford & Co. Sells 422,924 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health: Q4 Earnings Snapshot - Chron
Guardant Health Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Guardant Health’s Strong 2024 Growth and 2025 Outlook - TipRanks
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Liquid Biopsy Market Size Surges 14.5% CAGR to Soar $23.94 Billion by 2034 - BioSpace
Guardant Health Q4 Adjusted Loss Narrows, Revenue Rises; 2025 Sales Guidance Set - Marketscreener.com
Guardant Health reports Q4 revenue beat, raises 2025 guidance - Investing.com
Guardant Health reports Q4 revenue beat, raises 2025 guidance By Investing.com - Investing.com Nigeria
Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Earnings Flash (GH) Guardant Health Reports Q4 Revenue $201.8M, vs. FactSet Est of $192.1M - Marketscreener.com
Guyasuta Investment Advisors Inc. Acquires Shares of 6,740 Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Sees Large Drop in Short Interest - MarketBeat
Guardant Reveal aids organ preservation in rectal cancer treatment - MSN
Why Guardant Health, Inc. (GH) is the Best Performing Healthcare Stock So Far in 2025 - Insider Monkey
Austin clinics chosen to administer new blood tests to screen for colon cancer - FOX 7 Austin
10 Best Performing Healthcare Stocks So Far in 2025 - Insider Monkey
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.05%
2.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):